Recombinant Human Annexin A5 Ameliorates Localized Scleroderma by Inhibiting the Activation of Fibroblasts and Macrophages
Open Access
- 30 July 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (8) , 986
Abstract
Background: Localized scleroderma (LoS) is a chronic autoimmune condition marked by cutaneous fibrosis and persistent inflammation. Modulating the activation of inflammatory cells and fibroblasts remains a central strategy in LoS treatment. We investigate the anti-fibrotic effects of Annexin A5 (AnxA5), identified as a key inflammatory component in fat extract, and assess its therapeutic efficacy. Methods: In vitro experiments were performed using TGF-β-stimulated primary human dermal fibroblasts treated with recombinant AnxA5. The anti-fibrotic effects and underlying mechanisms were assessed using CCK-8 assays, quantitative real-time PCR, Western blotting, and immunocytochemistry. In vivo, AnxA5 was administered via both preventative and therapeutic protocols in bleomycin-induced LoS mouse models. Treatment outcomes were evaluated by histological staining, collagen quantification, immunostaining, and measurement of pro-inflammatory cytokines. Results: TGF-β stimulation induced myofibroblast differentiation and extracellular matrix (ECM) production in dermal fibroblasts, both of which were significantly attenuated by AnxA5 treatment through the inhibition of phosphorylation of Smad2. In vivo, both preventative and therapeutic administration of AnxA5 effectively reduced dermal thickness, collagen deposition, ECM accumulation, M1 macrophage infiltration, and levels of pro-inflammatory cytokines. Conclusions: Through both preventative and therapeutic administration, AnxA5 ameliorates LoS by exerting dual anti-fibrotic and anti-inflammatory effects, underscoring its potential for treating fibrotic diseases.Keywords
Funding Information
- Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research (2019CXJQ01)
This publication has 49 references indexed in Scilit:
- Recombinant human annexin A5 accelerates diabetic wounds healing by regulating skin inflammationRegenerative Therapy, 2024
- Annexin A5 as a targeting agent for cancer treatmentCancer Letters, 2022
- Dissolving microneedle rollers for rapid transdermal drug deliveryDrug Delivery and Translational Research, 2021
- Annexin A5 regulates hepatic macrophage polarization via directly targeting PKM2 and ameliorates NASHRedox Biology, 2020
- Transforming Growth Factor-β Signaling in Immunity and CancerImmunity, 2019
- Interstitial lung disease in the connective tissue diseases; a paradigm shift in diagnosis and treatmentClinical Immunology, 2018
- Controlled intra- and transdermal protein delivery using a minimally invasive Erbium:YAG fractional laser ablation technologyEuropean Journal of Pharmaceutics and Biopharmaceutics, 2013
- Topical use of systemic drugs in dermatology: A comprehensive reviewJournal of the American Academy of Dermatology, 2011
- Scleroderma: from cell and molecular mechanisms to disease modelsTrends in Immunology, 2005
- Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteinsBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1994